The company has long adhered to the implementation of product R&D and innovation strategies, and has established a R&D center since its establishment, which has a history of nearly 20 years. The company has established a complete R&D system and currently has more than 200 R&D personnel, of which about 25% are PhDs and about 70% are masters. One of them was selected into the eighth batch of the National Thousand Talents Plan, and two were selected into the 2012 “Jiangsu Province 333 High School Talents Program”. Hierarchical Talent Plan”. The R&D center consists of internal departments such as Medicinal Chemistry Department, Synthesis Technology Department, Analysis Department, Pharmacology Department, Preparation Department, Biopharmaceutical Department, Research Medicine Department, Registration and Project Management Department, and Comprehensive Management Department.
The company’s R&D center undertakes more than 20 major national and provincial scientific research projects such as the national “Major New Drug Creation” major science and technology project, the National High-Tech Research and Development Plan, the National Innovation Fund Project, the National Key New Product Project, and the National Torch Plan Project. Our R&D center has 4 nationally recognized research platforms: the National Incubation Base for Chiral Anti-infectious and Targeted Anti-tumor Innovative Drugs, the *** Postdoctoral Research Workstation, the Jiangsu Provincial Engineering Technology R&D Center, and the Jiangsu Provincial Enterprise Technology Center.
A major breakthrough has been made in independent innovation. At present, the company has applied for 99 domestic invention patents, of which 14 have submitted international PCT invention patent applications, with 34 authorized patents domestically and 8 overseas.